Small Cap Feast

17th April 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
 
Dish Of The Day:

Joiners: none today.

Whilst we were away: 
Wednesday 12th April — PanGenomic Health Inc, currently traded on the Canadian Securities Exchange market, has dual listed on the Access Segment of AQSE Growth Market.

Leavers: none today

Whilst we were away:
Tuesday 11th April — Beacon Energy has left AIM and will be re-introduced following a Reverse Takeover. 
Wednesday 12th April — Adept Technology Group Plc has left AIM. 
Friday 14th April — Devro Plc has left the Main Market of the London Stock Exchange.



What’s Cooking In The IPO Kitchen?

Ashoka WhiteOak Emerging Markets Trust Plc intends to join the Premium Segment of the London Stock Exchange. The Company is a new UK investment trust seeking to achieve long-term capital appreciation through investment primarily in quoted securities that provide exposure to global Emerging Markets and intends to raise £100m at 100p per ordinary share. Expected Admission 3 May 2023.

Drumz Plc is an investing company admitted to trading on AIM with an investment policy focused principally on acquiring investments in technology businesses based in Europe. Drumz currently has two investments, being a 25%. shareholding in Acuity Risk Management (ARM) and a 5.85% legacy shareholding in KCR Residential REIT plc (KCR). Admission to AIM is being sought as Drumz has conditionally agreed terms to acquire the remaining issued shares and to be issued shares in ARM for a total consideration of approximately £3.6m. Drumz plc will be renamed Acuity RM Group plc post Admission. The Company intends to raise £1.45m on Admission and will have a market capitalisation of £5.4m. Expected Admission 25th April 2023.

Vinanz Limited intends to join the Access Segment of the AQSE Growth Market. Vinanz Limited aims to build out a fullyfledged Bitcoin mining company initially focusing on installing clusters of Bitcoin miners in multiple decentralised data facilities throughout the US and Canada through third-party cryptocurrency mining providers such as Compass Mining. Whilst the Company will focus initially on BTC mining, it will also consider mining of other cryptocurrencies, and operations in the DeFi and Big Data space in the future. Expected Admission 21 April 2023.

M7 Box+ REIT plc, a newly established, externally managed closed-ended investment company announces that it intends to join the Wholesale segment of IPSX. Upon Admission, the Company proposes to acquire a portfolio of seven let and operational e-warehouses from M7 Box+ II LP. As at 31 December 2022, the Property Portfolio was valued at £228.9m. Expected Admission April 2023


Breakfast Buffet

Access Intelligence 79.5p £101.5m (ACC.L)
The technology innovator delivering Software-as-a-Service solutions for the global marketing and communications industries announces its final results for the year ended 30 November 2022. Revenue increased by 97% to £65.7m (2021: £33.3m). ARR base increased by 2% to £60.0m (2021: £58.9m), adjusted EBITDA of £2.3m (2021: loss of £0.5m), and cash balance was £4.9m (2021: £13.5m). New client wins in the EMEA, North America, and APAC regions including Airbnb, Allianz, Asahi. The Group continue to trade in line with expectations.

Cerillion £12.15 £358.6m (CER.L)
The billing, charging and customer relationship management software solutions provider announces an update on trading for the first six months of its current financial year ending 30 September 2023. Revenue is expected to be 27% higher at c.£20.5m (H1 2022: £16.1m), adjusted EBITDA is expected 38% higher at c.£9.9m (H1 2022: £7.2m) and net cash at 31 March 2023 is up by 43% to c.£23.6m (31 March 2022: £16.5m). The Board is confident that trading for the full year will be in line with consensus market forecasts.

Diaceutics 104p £87.9m (DXRX.L)
A leading technology and solutions provider to the pharmaceutical industry, reports its audited results for the year ended 31 December 2022. Revenue increased 40% to £19.5m (2021: £13.9m) with a shift to platform-based subscription contracts with 35% of revenue subscription based (2021: 3%), gross profit increased by 37% to £16.7m (2021: £12.2m), EBITDA of £3.6m (2021: £2.3m) and profit before tax £0.6m (2021: £0.5m). The Group looks forward in confidence and aims to partner with pharma or biotechs launching in precision medicine.

Intercede Group 64p £37.3m (IGP.L)
A cybersecurity software company specialising in digital identities, provides an update on trading for the year ending 31 March 2023 (FY23). Group revenues for FY23 are expected to be just over £12.0m (2022: £9.9m), approximately 21-22% higher than FY22 and ahead of market forecasts. Gross cash balances of £8.3m (2022: £7.8m). Post cash outflow of c.£2.3m relating to the acquisition of Authlogics, announced on 10 October 2022. The Group has no debt. The combined effect of revenue improvement and cost management, is expected in improved profitability subject to year end Audit.

Omega Diagnostics Group 2.65p £6.3m (ODX.L)
The specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, provides a trading update for the year ended 31 March 2023. The Company expects revenues of £7.5m (2022: £8.6m), in line with the expected revenue range. Higher raw material costs likely to result in an EBITDA loss for FY23 of c.£2.0m and cash position was £5.0m, in-line with expectations. Demand for the Company’s food sensitivity tests remains strong with an opening order book for FY24 of £2.4m. The Company remains confident in their FY24 results with revenue and EBITDA growth.

Quiz 12.6p £15.7m (QUIZ.L)
The omni-channel fashion brand provides a trading update covering the financial year ended 31 March 2023 (FY23). Revenue increased by 17% to £91.7m (FY22: £78.4m), Gross margins were in line with management expectations and consistent with the previous year. The group expects profitability of £2.0m (FY22: £0.8m) and net cash of £6.2m, comprising a cash balance of £7.6m offset by a £1.4m drawdown of available bank facilities (FY22: £4.4m). The Board remains confident and trading is in line with expectations.

Renold 28.4p £64.0m (RNO.L)
A leading international supplier of industrial chains and related power transmission products provides a trading update covering the year ended 31 March 2023 (FY23). Revenue for the year was £247.1m, a year-on-year increase of 26.6%, Group order intake during FY23 was £260.3m. This represents a year-on-year increase of 16.3% and the order book finished FY23 at £99.5m (31 March 2022: £84.1m). The Group has net debt of £29.8m (30 September 2022: £34.0m), a reduction of £4.2m in H2. The Board now expects underlying trading profit and margin to be materially ahead of the revised market expectations.

Supreme 109p £127.9m (SUP.L)
A leading manufacturer, supplier, and brand owner of fast-moving consumer products announces a trading update for the year ended 31 March 2023 (FY23). The Company expects FY23 revenue of at least £150m (2022: £130.8m) and adjusted EBITDA of at least £19.3m (2022: £21.1m). Expecting bank borrowings net of cash to be neutral as at 31 March 2023, a reduction of £12.9m since the half year. The Group expects to maintain strong growth, and trading for the year to be slightly ahead of current market expectations.

SysGroup 27p £13.3m (SYS.L)
The multi award-winning technology solutions provider provides a trading update for the year ended 31 March 2023 (FY23). Revenues grew 47% to £21.6m (FY22: £14.7m) and adjusted EBITDA increased 18% to £3.33m (FY22: £2.82m). Revenue growth was achieved through 6% organic growth and successful acquisitions of Truststream and Orchard both in April 2022. The Group has gross cash of £4.18m (FY22: £4.13m), achieved after payment of £5.8m for the Acquisitions and has a net debt position of £1.32m. The Group are trading in line with expectations and are well placed to execute their growth strategy.

Tekcapital 15.75p £26.0m (TEK.L)
The UK intellectual property investment group announces that it has raised a total of £2.0m (c.US$ 2.50m) before expenses at a price of 15p per share. Net proceeds will be primarily used to accelerate the growth of the Company’s portfolio companies including; £1m to build commercial inventory of MicroSalt Limited due to significant forthcoming orders, £0.5m for facility build out for Guident’s new Remote Control Monitoring Centre, and the remainder for additional working capital.

17 April 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram